Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FOXD1 antisense RNA 1 (FOXD1-AS1)
- Target
- FOXD1-AS1
- Molecular classification
- Long non-coding RNA, Other (lncRNA)
01
Overview
FOXD1 antisense RNA 1 (FOXD1-AS1) is a long non-coding RNA transcribed from the antisense strand of the FOXD1 gene. It is overexpressed in several cancers, including nasopharyngeal carcinoma and gastric cancer. FOXD1-AS1 promotes tumor cell proliferation, migration, invasion, and glycolysis, suppresses apoptosis, and is associated with aggressive disease and poor patient survival. It exerts its effects by upregulating FOXD1, a transcription factor linked with oncogenic signaling and poor prognosis. In gastric cancer, FOXD1-AS1 promotes chemoresistance by activating the PI3K/AKT/mTOR pathway. Currently, no clinical drugs target FOXD1-AS1 directly, but its elevated expression serves as a biomarker for unfavorable outcomes and represents a promising, emerging therapeutic target in oncology.
- Other names
- FOXD1-AS1TCONS_00009423
02
Mechanism of action
Sustains FOXD1 expression by acting as a regulatory RNA Activates PI3K/AKT/mTOR signaling pathway in gastric cancer, enhancing FOXD1 translation and promoting chemoresistance
03
Biological functions
Cell proliferationCell migrationCell invasionApoptosis inhibitionRegulation of glycolysisChemoresistance
04
Disease associations
Cancer (notably nasopharyngeal carcinoma, gastric cancer, potentially breast cancer via FOXD1 pathway)Chemoresistance
05
Safety considerations
Lack of specific inhibitorsTargeting lncRNAs may require careful assessment of off-target effects and tissue specificity
06
Biomarkers
High FOXD1-AS1 expression is a prognostic biomarker for poor survival in nasopharyngeal carcinoma
Beyond the preview
Go deeper on FOXD1 antisense RNA 1 (FOXD1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOXD1 antisense RNA 1 (FOXD1-AS1).